Clinical Lab Testing / Lab Processes and Procedures

Clinical laboratories: getting paid for molecular diagnostics tests

Clinical Laboratories: Getting Paid for Molecular Diagnostics TestsThe proliferation of molecular diagnostics is bringing a tidal wave of complexity, cost and quality issues for payers, clinicians and laboratories. As a result, payers are accelerating efforts to appropriately manage the utilization and reimbursement of molecular diagnostics and genetic tests.

To stay ahead of evolving requirements, successful laboratories are deploying technology to collaborate real-time with clinicians, payers and other laboratories. That’s the message in a newly-published White Paper, “Getting Paid for Molecular Tests: How Clinical Laboratories and Pathology Groups Should Respond to Pre-Authorization Requirements by Payers.

This White Paper is tailored specifically to any laboratory looking to further penetrate their market, increase clinician loyalty and better manage their utilization and relationships with payers. It is published by The Dark Report and Dark Daily and is available free to laboratory professionals as a PDF download.

This educational resource discusses why payer pre-authorization and/or notification for genetic molecular tests will become widespread, the existing differences among payers in pre-authorization of genetic and molecular tests and the advantages of automated payer communication.

A detailed case study reveals how one early adopter replaced its outreach laboratory test ordering with a new system that increased its revenue, decreased the number of claim denials and supported its new billing system.

The paper’s author, Matthew Zubiller, is vice president and general manager of McKesson’s Advanced Diagnostics Management business.  Zubiller’s team leads initiatives that advance McKesson’s role in the realm of personalized medicine, genetics and molecular diagnostics.

Reference: www.darkdaily.com

Line

About Randox

Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

*